16 research outputs found
N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma
Serum YKL-40:a new independent prognostic marker for skeletal complications in patients with multiple myeloma
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients
Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B
Background: Activins are members of the TGF-β family of ligands that have multiple biological functions in
embryonic stem cells as well as in differentiated tissue. Serum levels of activin A were found to be elevated in
pathological conditions such as cachexia, osteoporosis and cancer. Signaling by activin A through canonical
ALK4-ACVR2 receptor complexes activates the transcription factors SMAD2 and SMAD3. Activin A has a strong
affinity to type 2 receptors, a feature that they share with some of the bone morphogenetic proteins (BMPs). Activin
A is also elevated in myeloma patients with advanced disease and is involved in myeloma bone disease.
Results: In this study we investigated effects of activin A binding to receptors that are shared with BMPs using
myeloma cell lines with well-characterized BMP-receptor expression and responses. Activin A antagonized BMP-6
and BMP-9, but not BMP-2 and BMP-4. Activin A was able to counteract BMPs that signal through the type 2
receptors ACVR2A and ACVR2B in combination with ALK2, but not BMPs that signal through BMPR2 in combination
with ALK3 and ALK6.
Conclusions: We propose that one important way that activin A regulates cell behavior is by antagonizing
BMP-ACVR2A/ACVR2B/ALK2 signaling
High Serum Concentration of YKL-40 Is Associated with Short Survival in Patients with Acute Myeloid Leukemia
Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells
Objectives: A potential role in cancer biology is suggested for YKL-40 (CHI3L1, HC gp-39). The purpose of this study was to evaluate the clinical value of serum YKL-40 (sYKL-40) in multiple myeloma (MM) and to examine YKL-40 expression in malignant plasma cells (MM PCs). Methods: sYKL-40 was measured by enzyme-linked immunosorbent assay (ELISA) in 82 patients with newly diagnosed MM. YKL-40 expression in immunophenotypically defined plasma cells was investigated by double-labelled immunohistochemistry in 21 MM patients and by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in cDNA archives generated by global RT-PCR in seven controls, 14 patients with monoclonal gammopathy of undetermined significance (MGUS), 45 MM patients, nine patients with extramedullary myeloma (exMM), and seven human myeloma cell lines (HMCLs). Results: sYKL-40 was elevated above a constructed reference range for healthy controls in 29% of the patients investigated. Patients with elevated sYKL-40 had reduced overall survival and event-free survival when compared to patients with normal sYKL-40, but sYKL-40 level was defeated by beta(2)-microglobulin in the multivariate analyses. Intramedullary MM PCs lacked significant expression of YKL-40, but high levels of YKL-40 expression were seen in extramedullary MM PCs from one exMM patient and in six HMCLs. Further investigations of other bone marrow (BM) cells showed YKL-40 expression in megakaryocytes, neutrophils and adherent cells from long-term BM cultures. Conclusions: In newly diagnosed MM-patients, a sYKL-40 elevated above the reference range predicts a poor clinical outcome, and YKL-40 is expressed by other BM cells than MM PCs. At this point, routine measurements of sYKL-40 are not warranted, but YKL-40 should be considered as a potential player in the pathophysiology of MM